Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04353791

Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis Chronic Moderate Clinical Trial

Official title:
A Phase Ib/IIa, Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral Treatment With OST-122 in Patients With Moderate to Severe Ulcerative Colitis

Clinical Trial Summary

A Phase Ib/IIa to evaluate the safety and tolerability of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis over 28 days. This trial will also explore pharmacokinetics (PK) profile and preliminary therapeutic efficacy associated with OST-122 through biomarker analysis and clinical, endoscopic and histologic assessments.

Clinical Trial Description

OST-122 is an oral, gut-restricted and subtype-selective Jak3/Tyk2/Ark5 inhibitor for the local treatment of inflammatory bowel disease (IBD) including ulcerative colitis, Crohn's disease and, potentially, fibrotic lesions in Crohn's patients. The compound was well tolerated in a Phase 1 study in healthy volunteers and has been shown to be stable during the GI transit, while no significant plasma levels were detected. The gut-restricted PK profile of OST-122 lowers the risk of systemic toxicities inherent to other JAK inhibitors. In the current proof of concept study, the compound's safety, PK profile and trends of efficacy will be investigated in patients with moderate to severe ulcerative colitis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04353791
Study type Interventional
Source Oncostellae S.L
Contact
Status Completed
Phase Phase 1/Phase 2
Start date September 16, 2020
Completion date December 27, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT04102852 - Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients Phase 1/Phase 2
Recruiting NCT06311123 - Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis
Recruiting NCT05735665 - Comparison Between Bowel Ultrasound-based Treat to Target Versus Routine Treat to Target Strategies in Ulcerative Colitis N/A
Completed NCT03565939 - Probiotic Treatment of Ulcerative Colitis With Trichuris Suis Ova (TSO) Phase 2
Recruiting NCT03917095 - The Safety and Efficacy of TET Enema in the Treatment of UC N/A
Terminated NCT03923478 - ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis Phase 1
Not yet recruiting NCT06420492 - Study of Novel Therapeutics for Acute Remedy of Colitis Phase 2
Not yet recruiting NCT05912712 - Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum for the Topical Treatment of Rectal Mucosal Ulcers Phase 1
Recruiting NCT05666960 - R-3750 in Patients With Mild to Moderate Ulcerative Colitis Phase 1
Recruiting NCT05194007 - Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease Phase 2/Phase 3
Recruiting NCT05791487 - Combination of Diet and Oral Budesonide for Ulcerative Colitis N/A
Recruiting NCT03716388 - Fecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UC Phase 3
Completed NCT04504383 - PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC) Phase 2